HCA Healthcare, Inc. (NYSE: HCA) has reported its financial and operating results for the second quarter ended June 30, 2025, and has raised its 2025 guidance. Here are the key second-quarter metrics and how they compare to the same period in 2024:
- Revenues increased by 6.4% to $18.605 billion.
- Net income attributable to HCA Healthcare, Inc. increased by 13.1% to $1.653 billion.
- Diluted earnings per share increased by 23.5% to $6.83 per diluted share, and diluted earnings per share, as adjusted, increased by 24.4% to $6.84 per diluted share.
- Adjusted EBITDA increased by 8.4% to $3.849 billion.
- Cash flows from operating activities totaled $4.210 billion, compared to $1.971 billion in the second quarter of 2024.
- Same facility admissions increased by 1.8%, and same facility equivalent admissions increased by 1.7%.
- Same facility emergency room visits increased by 1.3%.
- Same facility inpatient surgeries declined by 0.3%, and same facility outpatient surgeries declined by 0.6%.
- Same facility revenue per equivalent admission increased by 4.0%.
As of June 30, 2025, HCA Healthcare, Inc.’s balance sheet reflected cash and cash equivalents of $939 million, total debt of $44.483 billion, and total assets of $59.536 billion. During the second quarter of 2025, capital expenditures totaled $1.176 billion, excluding acquisitions. Cash flows provided by operating activities in the second quarter of 2025 totaled $4.210 billion, compared to $1.971 billion in the second quarter of 2024.
The company repurchased 7.031 million shares of its common stock at a cost of $2.505 billion during the second quarter of 2025. The company had $5.753 billion remaining under its repurchase authorization as of June 30, 2025. As of that date, the company had $6.208 billion of availability under its credit facility.
HCA Healthcare, Inc. also declared a quarterly cash dividend of $0.72 per share on the company’s common stock, payable on September 30, 2025, to stockholders of record at the close of business on September 16, 2025.
The company has revised its 2025 estimated guidance ranges, with increases across various metrics compared to the previous guidance issued on January 24, 2025:
- Revenues: $74.00 to $76.00 billion (up from $72.80 to $75.80 billion)
- Net income attributable to HCA Healthcare, Inc.: $6.11 to $6.48 billion (up from $5.85 to $6.29 billion)
- Adjusted EBITDA: $14.70 to $15.30 billion (up from $14.30 to $15.10 billion)
- EPS (Diluted): $25.50 to $27.00 per diluted share (up from $24.05 to $25.85 per diluted share)
The company’s capital expenditures for 2025, excluding acquisitions, are estimated to be approximately $5.0 billion.
These figures reflect the company's expectations regarding volume growth, stable operating environment, payer mix, public policy developments, general business or economic conditions, inflation, and the impact of trade policies, among other factors. As a result of these announcements, the company's shares have moved -3.21% on the market, and are now trading at a price of $330.52. If you want to know more, read the company's complete 8-K report here.
